Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 22 February, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: 526953 | NSE: VENUSREM

Fundamental Analysis of Venus Remedies Ltd

About the Company - Venus Remedies Ltd

Venus Remedies Ltd. is a Public Limited Listed company incorporated on 15/09/1989 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1989PLC009705 and registration number is 009705. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 575.18 Cr. and Equity Capital is Rs. 13.37 Cr. for the Year ended 31/03/2022.
PharmaceuticalsS.C.O. 857, C. No. 10, 2nd Floor, Chandigarh Chandigarh
NamePosition Held
Mr. Pawan ChaudharyChairman & Managing Director
Dr.(Mrs.) Manu ChaudharyJoint Managing Director
Mr. Peeyush JainDeputy Managing Director
Mr. Ashutosh JainExecutive Director
Mr. Akshansh ChaudharyExecutive Director
Dr.(Mrs.) Savita GuptaIndependent Director
Mr. N P S MongaIndependent Director
Mr. Navdeep SudIndependent Director
Dr. Gilbert WenzelIndependent Director
Dr. S K ChadhaIndependent Director

Venus Remedies Ltd. Share Price Update

Share PriceValue
Previous Day₹373.20

Basic Stock Data of Venus Remedies Ltd

Market Cap 488 Cr.
Current Price 365
High / Low430/147
Stock P/E16.8
Book Value 352
Dividend Yield0.00 %
ROCE7.75 %
ROE5.90 %
Face Value 10.0

Data Source:

Competitors of Venus Remedies Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Nectar Lifescience Ltd 927 Cr. 41.345.7/14.4114 47.60.00 %0.18 %6.01 % 1.00
J B Chemicals & Pharmaceuticals Ltd 25,702 Cr. 1,6571,940/87550.0 1750.52 %22.4 %17.6 % 1.00
Morepen Laboratories Ltd 2,695 Cr. 52.756.4/24.035.4 15.40.00 %8.57 %5.93 % 2.00
Aarti Pharmalabs Ltd 4,754 Cr. 525595/26924.4 1830.38 %16.1 %13.2 % 5.00
Aarey Drugs & Pharmaceuticals Ltd 124 Cr. 49.068.0/21.929.5 46.80.00 %6.38 %3.33 % 10.0
Industry Average216.4 Cr133.850.6693.560.18%10.73%9.21%3.8

Venus Remedies Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit10.6518.084.4916.8227.3112.435.5414.5112.978.1024.6110.4017.79
OPM %8.45%14.83%4.03%12.96%13.48%10.00%3.89%10.14%9.27%6.92%15.81%10.93%10.61%
Other Income19.876.2924.051.962.891.222.251.441.793.813.412.263.05
Profit before tax14.5213.8618.2010.0221.464.700.237.895.774.5419.735.0514.34
Tax %10.26%15.95%-92.91%-16.77%-7.88%-20.21%-0.00%12.67%7.63%27.53%43.94%76.63%30.68%
Net Profit13.0311.6635.1111.7023.155.650.236.895.333.2911.061.189.94
EPS in Rs10.569.4528.458.7517.324.

Venus Remedies Ltd Quarterly Chart

Venus Remedies Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit10312013889815139334154626061
OPM %26%26%26%20%20%13%11%10%12%10%10%11%11%
Other Income0001222-3-44381013
Profit before tax51636934-22-28-30-849363844
Tax %7%9%7%-95%52%21%-11%4%-24%-27%-12%30%
Net Profit47576452-17-31-29-1062412725
EPS in Rs48.3354.3656.204.511.49-13.84-24.87-23.15-8.1050.0530.4619.8819.05
Dividend Payout %6%6%-0%-0%-0%-0%-0%-0%-0%-0%-0%-0%

Venus Remedies Ltd Profit & Loss Yearly Chart

YoY Net Profit Growth
YoY Net Profit Growth (%)21.28%12.28%-92.19%-60.00%-950.00%-82.35%6.45%65.52%720.00%-33.87%-34.15%
Change in YoY Net Profit Growth (%)0.00%-9.00%-104.47%32.19%-890.00%867.65%88.80%59.07%654.48%-753.87%-0.28%

Venus Remedies Ltd Growth

Compounded Sales Growth
10 Years:2%
5 Years:8%
3 Years:18%
Compounded Profit Growth
10 Years:-7%
5 Years:23%
3 Years:119%
Stock Price CAGR
10 Years:5%
5 Years:63%
3 Years:16%
1 Year:136%
Return on Equity
10 Years:3%
5 Years:4%
3 Years:9%
Last Year:6%

Venus Remedies Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital10111111111212121212131313
Other Liabilities557284647065821021001189798128
Total Liabilities574718834841843765751733644556580601640
Fixed Assets355401439444452406389364289262241216204
Other Assets196268327319310293297304330269314339407
Total Assets574718834841843765751733644556580601640

Venus Remedies Ltd Reserves and Borrowings Chart

Venus Remedies Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 4252536847593145781324137
Cash from Investing Activity -95-104-95-673-188-11-557-17-58
Cash from Financing Activity 535540-1-46-44-39-35-73-162-9-1
Net Cash Flow-03-2-13-40-1-02714-22

Venus Remedies Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days363745515543464333212451
Inventory Days156178173194219226246286296129118132
Days Payable202638403848527277764756
Cash Conversion Cycle1731901802042362212402572527495127
Working Capital Days88981151461791631441271667485112
ROCE %17%15%14%6%5%2%1%1%2%8%8%8%

Venus Remedies Ltd Financial Efficiency Indicators Chart

Venus Remedies Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
No. of Shareholders13,82914,41916,61718,23119,95221,18922,01522,24321,71920,49819,26719,560

Venus Remedies Ltd Shareholding Pattern Chart

No. of Venus Remedies Ltd Shareholders

This stock is not held by any mutual fund

Venus Remedies Ltd ROCE Trend

Venus Remedies Ltd EPS Trend

Venus Remedies Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)19.8830.8650.04-8.10-23.15
Diluted EPS (Rs.)19.8830.8650.04-8.10-23.15
Cash EPS (Rs.)44.0455.5578.6317.844.38
Book Value[Excl.RevalReserv]/Share (Rs.)344.38329.50324.33262.01269.42
Book Value[Incl.RevalReserv]/Share (Rs.)344.38329.50324.33262.01269.42
Revenue From Operations / Share (Rs.)415.58447.86444.11274.94260.81
PBDIT / Share (Rs.)52.7652.6859.4837.3731.29
PBIT / Share (Rs.)28.6027.6030.9011.443.76
PBT / Share (Rs.)28.3827.2439.34-6.51-24.09
Net Profit / Share (Rs.)19.8730.4750.04-8.10-23.15
NP After MI And SOA / Share (Rs.)19.8730.4750.04-8.10-23.15
PBDIT Margin (%)12.6911.7613.3913.5911.99
PBIT Margin (%)6.886.166.954.151.44
PBT Margin (%)6.826.088.85-2.36-9.23
Net Profit Margin (%)4.786.8011.26-2.94-8.87
NP After MI And SOA Margin (%)4.786.8011.26-2.94-8.87
Return on Networth / Equity (%)5.779.2415.43-3.09-8.59
Return on Capital Employeed (%)7.377.578.313.360.98
Return On Assets (%)4.417.0211.11-1.56-3.89
Long Term Debt / Equity (X)
Total Debt / Equity (X)
Asset Turnover Ratio (%)0.901.010.860.460.40
Current Ratio (X)3.913.002.381.321.01
Quick Ratio (X)2.461.641.150.670.46
Inventory Turnover Ratio (X)2.653.042.641.221.36
Interest Coverage Ratio (X)239.55146.415.643.461.52
Interest Coverage Ratio (Post Tax) (X)91.2485.673.940.910.22
Enterprise Value (Cr.)205.06351.82361.07183.27266.93
EV / Net Operating Revenue (X)0.360.580.650.540.82
EV / EBITDA (X)2.915.004.923.976.91
MarketCap / Net Operating Revenue (X)0.380.600.610.080.12
Price / BV (X)0.470.810.840.080.12
Price / Net Operating Revenue (X)0.380.600.610.080.12

Venus Remedies Ltd Profitability Ratios (%)

Venus Remedies Ltd Liquidity Ratios

Venus Remedies Ltd Liquidity Ratios (%)

Venus Remedies Ltd Interest Coverage Ratios (X)

Venus Remedies Ltd Valuation Ratios

Fair Value / Intrinsic Value of Venus Remedies Ltd

Fair Value: ₹355.88

The stock is overvalued by 2.50% compared to the current price ₹365

*Investments are subject to market risks

Strength and Weakness of Venus Remedies Ltd

  1. The company has higher reserves (387.46 cr) compared to borrowings (211.62 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (456.69 cr) and profit (20.92 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 20.46 and average Dividend Yield of 5.12%.
  2. The stock has a low average ROCE of 7.25%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 124.75, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 187.42, which may not be favorable.

Should I Buy Venus Remedies Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Venus Remedies Ltd:
    1. Net Profit Margin: 4.78%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 7.37% (Industry Average ROCE: 24.16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): 91.24
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 2.46
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✓ Stock P/E: 16.8 (Industry average Stock P/E: 18.16)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.09
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Venus Remedies Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE